Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension

European Heart Journal

Volumn 34, Issue 28, 2013, Pages 2114-2121

  Kiuchi, Márcio Galindo ^a,b   Maia, George Luiz Marques ^b   De Queiroz Carreira, Maria Angela Magalhães ^b   Kiuchi, Tetsuaki ^b   Chen, Shaojie ^c   Andrea, Bruno Rustum ^d   Graciano, Miguel Luis ^a   Lugon, Jocemir Ronaldo ^a,e  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b Hospital Regional Darcy Vargas   (Brazil)

^c THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO   (Brazil)

Author keywords

Blood pressure reduction; Chronic kidney disease; Hypertension; Improvement of renal function; Renal denervation

Indexed keywords

ALBUMIN; ALISKIREN; AMLODIPINE; ATENOLOL; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; CLONIDINE; CREATININE; DILTIAZEM; DOXAZOSIN; ENALAPRIL; FELODIPINE; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LOSARTAN; MANIDIPINE; METOPROLOL; NIFEDIPINE; NITRENDIPINE; PROPRANOLOL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VALSARTAN; VERAPAMIL;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CATHETER ABLATION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DENERVATION; KIDNEY FUNCTION; LONGITUDINAL STUDY; MALE; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESISTANT HYPERTENSION; STANDARD IRRIGATED CARDIAC ABLATION CATHETER; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

BLOOD PRESSURE REDUCTION; CHRONIC KIDNEY DISEASE; HYPERTENSION; IMPROVEMENT OF RENAL FUNCTION; RENAL DENERVATION;

ALBUMINURIA; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CATHETER ABLATION; CHRONIC DISEASE; CREATININE; DRUG RESISTANCE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84880942362     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht200     Document Type: Article

References (37)

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108: 2154-2169.
2. Walker WG. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am J Kidney Dis 1993;22: 164-173.
3. Sarafidis PA, Sharpe CC, Wood E, Blacklock R, Rumjon A, Al-Yassin A, Ariyanayagam R, Simmonds S, Fletcher-Rogers J, Vinen K. Prevalence, patterns of treatment, and control of hypertension in predialysis patients with chronic kidney disease. Nephron Clin Pract 2012;120: c147-c155.
4. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof-of-principle cohort study. Lancet 2009;373: 1275-1281.
5. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011;57: 911-917.
6. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376: 1903-1909.
7. Voskuil M, Verloop WL, Blankestijn PJ, Agostoni P, Stella PR, Doevendans PA. Percutaneous renal denervation for the treatment of resistant essential hypertension: the first Dutch experience. Neth Heart J 2011;19: 319-323.
8. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011;123: 1940-1946.
9. Ahmed H, Neuzil P, Skoda J, Petru J, Sediva L, Schejbalova M, Reddy VY. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv 2012;5: 758-65.
10. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, Shirokova N, Karaskov A, Mittal S, Steinberg JS. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012;60: 1163-70.
11. Prochnau D, Lauten A, Busch M, Kuehnert H, Figulla HR, Surber R. Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter. Euro Intervention 2012;7: 1077-80.
12. Prochnau D, Figulla HR, Surber R. Efficacy of renal denervation with a standard EP catheter in the 24-h ambulatory blood pressure monitoring-long-term follow-up. Int J Cardiol 2012;157: 447-8.
13. Augustyniak RA, Tuncel M, Zhang W, Toto RD, Victor RG. Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens 2002;20: 3-9.
14. Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002;15: 717-724.
15. Tinucci T, Abrahao SB, Santello JL, Mion DJr. Mild chronic renal insufficiency induces sympathetic overactivity. J Hum Hypertens 2001;15: 401-406.
16. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation 2002;106: 1974-1979.
17. Yu XQ. Hypertension is an independent risk factor for progression of chronic kidney disease. Zhonghua Nei Ke Za Zhi 2009;48: 443-444.
18. Stojceva-Taneva O, Selim G, Stojkovski L, Ivanovski N. Hypertension and progression of nephropathy in diabetic and non-diabetic chronic kidney disease patients. Hippokratia 2007;11: 72-76.
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39 (Suppl 1): S1-S266.
20. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150: 604-612.
21. Sociedade Brasileira de Cardiologia, Sociedade Brasileira de Hipertensão, Sociedade Brasileira de Nefrologia. VI Diretrizes Brasileiras de Hipertensão. Arq Bras Cardiol 2010;95: 1-51.
22. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL; The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28: 1462-1536.
23. Merten GJ, Burgess WP, Rittase RA, Kennedy TP. Prevention of contrast-induced nephropathy with sodium bicarbonate: an evidence-based protocol. Crit Path Cardiol 2004;3: 138-143.
24. ten Dam MA, Wetzels JF. Toxicity of contrast media: an update. Neth J Med 2008;66: 416-422.
25. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012;23: 1250-1257.
26. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bombelli M, Cuspidi C, Facchetti R, Bolla G, Mancia G. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension 2008;52: 925-931.
27. Dahm JB, Wolpers HG, Becker J, Daume B, Hansen C. Renal sympathetic denervation - physical-anatomical basics, procedure, and analysis of clinical and technical parameters on procedure success and efficacy. Dtsch Med Wochenschr 2012;137: 1904-1909.
28. Jaïs P, Shah DC, Haïssaguerre M, Hocini M, Garrigue S, Le Metayer P, Clémenty J. Prospective randomized comparison of irrigated-tip versus conventional-tip catheters for ablation of common flutter. Circulation 2000;101: 772-776.
29. Atherton DS, Deep NL, Mendelsohn FO. Micro-anatomy of the renal sympathetic nervous system: a human post-mortem histologic study. Clin Anat 2012;25: 628-33.
30. Grassi G, Bertoli S, Seravalle G. Sympathetic nervous system: role in hypertension and in chronic kidney disease. Curr Opin Nephrol Hypertens 2012;21: 46-51.
31. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009;54: 690-697.
32. Park J, Campese VM, Nobakht N, Middlekauff HR. Differential distribution ofmuscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol 2008;105: 1873-1876.
33. Grassi G, Seravalle G, Arenare F, Buccianti G, Furiani S, Ilardo V, Bolla G, Mancia G. Behaviour of regional adrenergic outflow in mild-to-moderate renal failure. J Hypertens 2009;27: 562-566.
34. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell'Oro R, Mancia G. Early sympathetic activation in the initial clinical stages of chronic renal failure. First demonstration of increased sympathetic neural discharge in mild-to-moderate renal failure. Hypertension 2011;57: 846-851.
35. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997;77: 75-197.
36. Norvell JE, Weitsen HA, Dwyer JJ. Degeneration and regeneration of adrenergic nerves in the autotransplanted kidney. Transplantation 1969;7: 218-220.
37. Baylis C, Brenner BM. The physiologic determinants of glomerular ultrafiltration. Rev Physiol Biochem Pharmacol 1978;80: 1-46.